Source: Andrew Wynn
Evercore ISI Maintains “Outperform” Rating for AbbVie Inc.
Evercore ISI, one of the world’s leading independent investment banking advisory firms, has reaffirmed its “Outperform” rating for AbbVie Inc. (NYSE:ABBV), a global biopharmaceutical company. The firm is known for its deep industry analysis and rigorous rating system. Despite adjusting the price target from $232 to $228, Evercore ISI’s continued confidence in AbbVie underscores the company’s potential for future growth and outperformance in the market.
AbbVie Competes with Industry Giants
AbbVie Inc. is a major player in the biopharmaceutical arena, competing with other industry titans like Pfizer and Johnson & Johnson. The company is renowned for delivering innovative treatments in immunology, oncology, and neuroscience. As of February 4, 2026, AbbVie’s stock was priced at $218.69, slightly below the new Evercore ISI target price.
Impressive Financial Performance in Q4 2025
In the fourth quarter of 2025, AbbVie demonstrated financial prowess, with sales reaching a substantial $16.62 billion. This figure notably surpassed the consensus estimate of $16.42 billion, representing a 10% increase on a reported basis and a 9.5% increase on an operational basis. The company’s adjusted earnings per share also rose significantly by 25.5% to $2.71, exceeding the expected $2.65. This performance underscores AbbVie’s profitability and its potential for sustained growth.
Growth Driven by Immunology Portfolio
A significant driver of AbbVie’s financial growth was its immunology portfolio, which generated global net revenues of $8.63 billion, reflecting an 18.3% increase. Specifically, sales of Skyrizi and Rinvoq, two of AbbVie’s newer immunology drugs, surged by 32.5% and 29.5% to $5.01 billion and $2.37 billion, respectively. However, the sales of Humira, one of AbbVie’s legacy products, experienced a decline of 25.9%, totaling $1.25 billion.
Neuroscience and Oncology Portfolios Show Mixed Results
In the neuroscience portfolio, sales climbed to $2.96 billion, a 17.9% increase. Vraylar and Botox Therapeutics both contributed to this growth with net revenues of $1.02 billion and $991 million, respectively. Meanwhile, the oncology portfolio faced a slight decline, generating $1.66 billion in sales, down 1.5%. This was primarily due to Imbruvica’s net revenues falling by 20.8% to $671 million, while Venclexta’s revenues increased by 8.6% to $711 million.
2026 Profit Projections Surpass Wall Street Estimates
Despite some challenges, AbbVie projects its 2026 profit to surpass Wall Street estimates, driven by robust sales of its newer immunology drugs, Skyrizi and Rinvoq. The stock currently trades at $216.97, reflecting a decrease of 3.85% or $8.69. However, the stock has fluctuated between a low of $204.27 and a high of $220.85 on the day. With a market capitalization of approximately $383.47 billion, the company continues to hold a substantial position in the biopharmaceutical sector.
In conclusion, the reaffirmed “Outperform” rating by Evercore ISI, coupled with impressive Q4 2025 performance and promising projections for 2026, position AbbVie Inc. as a potentially lucrative investment opportunity in the biopharmaceutical industry. Despite the adjusted price target and some fluctuation in the stock price, the company’s capabilities to drive sales, particularly in its immunology portfolio, may provide considerable returns for investors in the long run.